Patents by Inventor Peter G. Schultz

Peter G. Schultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting agent antibody conjugates and uses thereof
    Patent number: 11377496
    Abstract: Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: July 5, 2022
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Chanhyuk Kim, Jun Y. Axup, Hwayoung Yun, Peter G. Schultz, Jennifer Ma, Jiayin Shen, Pengyu Yang
  • MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
    Publication number: 20220072104
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: March 10, 2022
    Inventors: Weijun SHEN, Pengyu YANG, Peter G. SCHULTZ
  • METHODS, APPARATUSES, SYSTEMS AND DEVICES FOR MOBILE DIGITAL SPATIAL PROFILING OF PATHOLOGICAL SPECIMENS
    Publication number: 20220076809
    Abstract: Embodiments of the present disclosure are directed to a compact, mobile, digital spatial profiling (DSP) system, and associated apparatuses, devices and methods, which are configured to image one or more regions-of-interest (ROIs), and then using UV light to cleave, for example, oligos off antibodies in one or more ROIs (“photocleaving”), and collect the photocleaved oligos for later hybridization and counting.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Inventors: Joseph M. BEECHEM, Dwayne DUNAWAY, Jaemyeong JUNG, Peter G. SCHULTZ, Eliot SOSIN, Grant TREMEL
  • CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF
    Publication number: 20220073597
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Application
    Filed: August 30, 2021
    Publication date: March 10, 2022
    Inventors: Travis S. YOUNG, Leonard PRESTA, David RODGERS, Eric HAMPTON, Timothy WRIGHT, Peter G. SCHULTZ, Eduardo LABORDA, Elvira KHIALEEVA, Sophie VIAUD
  • RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE
    Publication number: 20220048969
    Abstract: Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 17, 2022
    Inventors: Feng WANG, Yan LIU, Ying WANG, Guangsen FU, Peter G. SCHULTZ
  • MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
    Publication number: 20220000981
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: May 11, 2021
    Publication date: January 6, 2022
    Inventors: Weijun SHEN, Pengyu YANG, Huafei ZOU, Peter G. SCHULTZ
  • METHODS FOR INDUCING CHONDROGENESIS
    Publication number: 20210361600
    Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes using intra-articular administration.
    Type: Application
    Filed: April 23, 2018
    Publication date: November 25, 2021
    Inventors: Peter G. SCHULTZ, Arnab K. CHATTERJEE, Timothy M. WRIGHT, John WISLER, Vadim KLYUSHNICHENKO
  • Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
    Patent number: 11174306
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 16, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis S. Young, Leonard Presta, David Rodgers, Eric Hampton, Timothy Wright, Peter G. Schultz, Eduardo Laborda, Elvira Khialeeva, Sophie Viaud
  • Relaxin immunoglobulin fusion proteins and methods of use
    Patent number: 11161891
    Abstract: Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: November 2, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Feng Wang, Yan Liu, Ying Wang, Guangsen Fu, Peter G. Schultz
  • Optimized PNE-based chimeric receptor T cell switches and uses thereof
    Patent number: 11091546
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 17, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis Young, David T. Rodgers, Ian Hardy, Chanhyuk Kim, Peter G. Schultz, Eric Hampton, Eduardo Laborda, Leonard Presta
  • AGONISTS OF STIMULATOR OF INTERFERON GENES STING
    Publication number: 20210205321
    Abstract: The invention provides compounds having STimulator of INterferon Genes (STING) agonistic bioactivity that can be used in the treatment of tumors in patients afflicted therewith. The compounds are of formula (I): as defined herein. Compounds for practice of a method of the invention can be delivered via oral delivery for systemic exposure, as well as delivered intratumorally. Antitumor therapy using a compound of formula (I) can further comprise administration of an effective dose of an immune-checkpoint targeting drug.
    Type: Application
    Filed: February 21, 2019
    Publication date: July 8, 2021
    Inventors: Luke L. Lairson, Emily Chin, Arnab K. Chatterjee, Manoj Kumar, Ana Maria Gamo Albero, Hank Michael James Petrassi, Peter G. Schultz, Chenguang Yu, Junko Tamiya, William Vernier, Anil Gupta, Ramkumar Modukuri
  • SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES
    Publication number: 20210196713
    Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.
    Type: Application
    Filed: October 30, 2018
    Publication date: July 1, 2021
    Applicants: The Scripps Research Institute, Board of Regents, The University of Texas System
    Inventors: Luke L. Lairson, Michael J. Bollong, Peter G. Schultz, Sendurai A. Mani
  • Compounds and methods for inducing chondrogenesis
    Patent number: 11045476
    Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: June 29, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Peter G. Schultz, Arnab K. Chatterjee, Shoutian Zhu, Joshua Payette, Hongchul Yoon, Baiyuan Yang
  • COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS
    Publication number: 20210187033
    Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 24, 2021
    Inventors: Anthony Edward Boitano, Michael Cooke, Shifeng Pan, Peter G. Schultz, John Edward Tellew, Yongqin Wan, Xing Wang
  • ANTIMALARIAL COMPOSITIONS AND USES THEREOF
    Publication number: 20210179524
    Abstract: Provided herein are compounds, compositions and method of using thereof to treat or prevent malaria.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 17, 2021
    Inventors: WIL JOSEPH ANDAHAZY, ARNAB K. CHATTERJEE, CASE W. MCNAMARA, FEDERICO C. BEASLEY, ANDERS MIKAL ELIASEN, HANK MICHAEL JAMES PETRASSI, JASON T. ROLAND, TIMOTHY WELLS, OLGA VLADIMIROVNA ZATOLOCHNAYA, FEI ZHOU, PETER G. SCHULTZ, ANIL KUMAR GUPTA
  • Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
    Patent number: 11007252
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 18, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • Modified therapeutic agents and compositions thereof
    Patent number: 10987427
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: April 27, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Peter G. Schultz, Avinash Muppidi, Insha Ahmad, Pengyu Yang
  • Antimalarial compositions and uses thereof
    Patent number: 10947176
    Abstract: Provided herein are compounds, compositions and method of using thereof to treat or prevent malaria.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: March 16, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Wil Joseph Andahazy, Arnab K. Chatterjee, Case W. McNamara, Federico C. Beasley, Anders Mikal Eliasen, Hank Michael James Petrassi, Jason T. Roland, Timothy Wells, Olga Vladimirovna Zatolochnaya, Fei Zhou, Peter G. Schultz, Anil Kumar Gupta
  • COMPOSITION AND METHODS FOR INHIBITING MAMMALIAN STERILE 20-LIKE KINASE 1
    Publication number: 20210061784
    Abstract: Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.
    Type: Application
    Filed: August 20, 2020
    Publication date: March 4, 2021
    Inventors: Hank Michael James PETRASSI, Murali Mohan Reddy PERAM SURAKATTULA, Kathrin MAEDLER, Amin ARDESTANI, Jason T. ROLAND, Tyler D. BAGULEY, Matthew S. TREMBLAY, Weijun SHEN, Peter G. SCHULTZ, Arnab K. CHATTERJEE
  • Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
    Patent number: 10800828
    Abstract: Disclosed herein are switchable chimeric receptors, switchable chimeric receptor effector cells and chimeric receptor effector cell switches. The switchable chimeric receptor-ECs are generally T cells. The chimeric receptors have non-antibody extracellular domains that recognize a chimeric receptor binding partner on the chimeric receptor-EC switch or target cell. The chimeric receptor-ECs and switches may be used for the treatment of a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: October 13, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Travis Young, Chanhyuk Kim, Peter G. Schultz